##Sacituzumab
LightNews LightNews
oncodaily.bsky.social
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

https://oncodaily.com/drugs/sacituzumab-193201

##AntibodyDrugConjugate ##Cancer ##ChinasNationalMedicalProductsAdministration ##NMPA ##OncoDaily ##Oncology ##Sacituzumab ##Tirumotecan
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC - OncoDaily
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC / antibody-drug conjugate, cancer, China's National Medical Products
oncodaily.com
December 3, 2024 at 9:01 AM
newsen.bsky.social
Kelun-Biotech to Showcase Groundbreaking Studies on NSCLC Treatments at ASCO 2026#USA#Chicago#Kelun-Biotech#Sacituzumab#Pembrolizumab
Kelun-Biotech to Showcase Groundbreaking Studies on NSCLC Treatments at ASCO 2026
Kelun-Biotech is set to present influential studies on innovative lung cancer treatments at ASCO 2026, highlighting significant advancements.
third-news.com
May 22, 2026 at 12:04 AM
newsen.bsky.social
Discover the Latest Findings on Sacituzumab Tirumotecan at ESMO 2026 in Madrid#Spain#Madrid#Sacituzumab#Lung_Cancer#ESMO_2026
Discover the Latest Findings on Sacituzumab Tirumotecan at ESMO 2026 in Madrid
The ESMO 2026 Congress in Madrid will showcase groundbreaking studies on Sacituzumab Tirumotecan, exploring its impact on lung and endometrial cancers.
third-news.com
September 22, 2026 at 7:50 AM
newsen.bsky.social
Sacituzumab Govitecan Receives FDA Approval for Treating Metastatic Triple-Negative Breast Cancer#United_States#FDA_Approval#Sacituzumab#Foster_City#Metastatic_Breast_Cancer
Sacituzumab Govitecan Receives FDA Approval for Treating Metastatic Triple-Negative Breast Cancer
The approval of Sacituzumab Govitecan marks a significant advance in the treatment options for metastatic triple-negative breast cancer patients, ensuring better outcomes.
third-news.com
July 8, 2026 at 4:24 AM
newsen.bsky.social
Latest Findings on Sacituzumab Govitecan and Pembrolizumab in Treating NSCLC Fail to Show Significant Progress#South_Korea#Seoul#Sacituzumab#NSCLC#Pembrolizumab
Latest Findings on Sacituzumab Govitecan and Pembrolizumab in Treating NSCLC Fail to Show Significant Progress
Recent research reveals that Sacituzumab govitecan combined with pembrolizumab did not provide significant survival advantages for NSCLC patients, despite longer progression-free survival.
third-news.com
September 13, 2026 at 11:59 AM
newsen.bsky.social
Groundbreaking Approval for Lifesaving Treatment in Europe for TNBC Patients#None#Sacituzumab#TNBC#Pembrolizumab
Groundbreaking Approval for Lifesaving Treatment in Europe for TNBC Patients
The European Commission approves a groundbreaking combination therapy for triple-negative breast cancer, marking a significant advancement in treatment options for patients.
third-news.com
September 7, 2026 at 4:31 AM
gbg.de
#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery
October 29, 2025 at 7:57 AM
currentmedscience.bsky.social
Data from multiple sources provide insights into the safety profile of #Sacituzumab #Govitecan (SG), identifying common hematologic toxicities and unexpected #AdverseEffects, underscoring the need for critical clinical monitoring & management.

Read: doi.org/10.1007/s115...
Toxicities Associated with Sacituzumab Govitecan
December 23, 2025 at 5:45 AM
newsen.bsky.social
Kelun-Biotech's Promising Study Results of Sacituzumab Tirumotecan in Gynecologic Cancers Unveiled at 2026 SGO#China#Chengdu#Kelun-Biotech#Sacituzumab#TROP2_ADC
Kelun-Biotech's Promising Study Results of Sacituzumab Tirumotecan in Gynecologic Cancers Unveiled at 2026 SGO
Kelun-Biotech has announced encouraging findings for sacituzumab tirumotecan as a treatment for gynecological cancers, presented at SGO 2026.
third-news.com
April 14, 2026 at 12:05 AM
newsen.bsky.social
Novel TROP2 ADC Sacituzumab Tirumotecan Shows Promising Results in Urothelial Carcinoma#China#Chengdu#Kelun-Biotech#Sacituzumab#Urothelial_Carcinoma
Novel TROP2 ADC Sacituzumab Tirumotecan Shows Promising Results in Urothelial Carcinoma
A recent Phase II study published in the Annals of Oncology highlights the efficacy of sacituzumab tirumotecan, offering new hope for patients with advanced urothelial carcinoma.
third-news.com
November 28, 2025 at 4:20 AM
newsen.bsky.social
Kelun-Biotech Showcases Promising Clinical Findings for TROP2 ADC in Cancer Treatment at CCHIO 2025#China#ADC#Kelun-Biotech#Sacituzumab#Kunming
Kelun-Biotech Showcases Promising Clinical Findings for TROP2 ADC in Cancer Treatment at CCHIO 2025
At the 2025 CCHIO Congress, Kelun-Biotech revealed compelling outcomes from various clinical trials on its TROP2 ADC, sacituzumab tirumotecan.
third-news.com
November 10, 2025 at 2:06 AM
newsen.bsky.social
Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan Published in NEJM#China#Chengdu#Sacituzumab#NSCLC#EGFR-TKI
Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan Published in NEJM
The New England Journal of Medicine reveals significant findings from the Phase III OptiTROP-Lung04 study on sacituzumab tirumotecan for NSCLC, highlighting its efficacy.
third-news.com
October 20, 2025 at 9:13 AM
newsen.bsky.social
Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine#China#Chengdu#Sacituzumab#NSCLC#Tagitanlimab
Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine
Recent findings from a Phase II study reveal promising results for a novel treatment regime for advanced non-small cell lung cancer (NSCLC), combining sacituzumab tirumotecan and tagitanlimab.
third-news.com
August 19, 2025 at 11:51 AM
newsen.bsky.social
Kelun-Biotech Reports Strong Financial Performance and Pipeline Advances for 2025#China#Chengdu#oncology#Kelun-Biotech#Sacituzumab
Kelun-Biotech Reports Strong Financial Performance and Pipeline Advances for 2025
Kelun-Biotech has announced impressive interim results for 2025, showing significant revenue growth and advancements in oncology and non-oncology pipeline projects amidst a shifting biopharmaceutical landscape.
third-news.com
August 18, 2025 at 10:36 AM
newsen.bsky.social
Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal#China#Chengdu#Kelun-Biotech#Sacituzumab#TROP2_ADC
Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal
Sichuan Kelun-Biotech announces significant findings on sacituzumab tirumotecan (sac-TMT), published in Nature Medicine, marking a major advancement for cancer treatment.
third-news.com
April 12, 2025 at 8:55 AM
newsen.bsky.social
Kelun-Biotech's Sacituzumab Tirumotecan Gains Approval for Second Lung Cancer Indication#China#Chengdu#Kelun-Biotech#Sacituzumab#Lung_Cancer
Kelun-Biotech's Sacituzumab Tirumotecan Gains Approval for Second Lung Cancer Indication
Sichuan Kelun-Biotech has received marketing approval for Sacituzumab Tirumotecan, increasing treatment options for patients with EGFR-positive NSCLC.
third-news.com
March 10, 2025 at 10:50 AM
newsen.bsky.social
Kelun-Biotech's Sacituzumab Tirumotecan Gains Chinese Approval for Advanced TNBC Treatment#China#Chengdu#Kelun-Biotech#Sacituzumab#TNBC
Kelun-Biotech's Sacituzumab Tirumotecan Gains Chinese Approval for Advanced TNBC Treatment
Kelun-Biotech announces its innovative drug, Sacituzumab Tirumotecan, receives marketing approval for advanced TNBC in China, marking a significant milestone.
third-news.com
November 27, 2024 at 6:38 AM